Personal use of HRT by postmenopausal women doctors and doctors' wives in the north of Italy

References

• Chiaffarino F, Parazzini F, La Vecchia C, et al. Correlates of hormone replacement therapy use in Italian women, 1992-1996. Maturitas 1999;33: 107–15
   PubMed Web of Science ®Google Scholar
• Pansini F, Bacchi Modena AB, de Aloysio D, et al. Sociodemographic and clinical factors associated with HRT use in women attending menopause clinics in Italy. Climacteric 2000;3:241–7
   PubMedGoogle Scholar
• Mueller JE, Doring A, Heier M, Lowel H. Prevalence and determinants of hormone replacement therapy in German women 1984-1995. Maturitas 2002;43: 95–104
   PubMed Web of Science ®Google Scholar
• Brett K. Racial differences in hormone replacement therapy use. United States, 1999–2000. Ann Epidemiol 2002;12: 514–15
   Google Scholar
• Friedman-Koss D, Crespo CJ, Bellantoni MF, Andersen RE. The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988–1994. Menopause 2002;9: 264–72
   Google Scholar
• Brett KM, Reuben CA. National use of HRT: the influence of regular obstetrician/gynecologist visits. Presented at 13th NAMS meeting, October 2002, Chicago, IL
   Google Scholar
• Armstrong K, Popik S, Guerra C, Ubel PA. Beliefs about breast cancer risk and use of postmenopausal hormone replacement therapy. Med Decis Making 2000;20:308–13
   PubMed Web of Science ®Google Scholar
• Bakken K, Eggen AE, Lund E. Hormone replacement therapy in Norwegian women, 1996–1997. Maturitas 2001;40: 131–41
   Google Scholar
• Kaplan B, Aschkenazi-Steinberg S, Yogev Y, et al. Gynecologists' trends and attitudes toward prescribing hormone replacement therapy during menopause. Menopause 2002;9:354–9
   PubMed Web of Science ®Google Scholar
• Andersson K, Pedersen AT, Mattson LA, Milsom I. Swedish gynecologists' and general practitioners' views on the climacteric period: knowledge, attitudes and management strategies. Acta Obstet Gynecol Scand 1998;77:909–16
   PubMed Web of Science ®Google Scholar
• Nilsen ST, Fredriksen T, Iversen OE, Moen MH. Attitude to and practice of Norwegian gynecologists concerning hormone replacement therapy in climac-teric. Tidsskr Nor Laegeforen 1998;118:2940–3
   PubMedGoogle Scholar
• Gupta S, Forbes N, Kirkman R. Attitudes to meno-pause and hormone replacement therapy among Asian and Caucasian women general practitioners. Maturitas 2001;39:169–75
   Google Scholar
• McNagny SE, Wegner NK, Frank E. Personal use of postmenopausal hormone replacement therapy by women physicians in the United States. Ann Intern Med 1997;127:1093–6
   Google Scholar
• Fallon U, Kelleher C. Hormone replacement therapy: a survey of Irish general practitioners. Ir Med J 2000; 93:10–11
   PubMedGoogle Scholar
• Kaplan B, Yogev Y, Sulkas J, et al. Attitude towards health and hormone replacement therapy among female obstetrician—gynecologists in Israel. Maturitas 2002;43:113–16
   PubMed Web of Science ®Google Scholar
• Isaacs AJ, Britton AR, McPherson K. Why do the women doctors in the UK take hormone replace-ment therapy? J Epidemiol Community Health 1997; 51:373–7
   Google Scholar
• Finley C, Gregg EW, Solomon 14, Gay E. Disparaties in hormone replacement therapy use by socio-economic status in a primary care population. J Community Health 2001;26:39–50
   Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–33
   Google Scholar
• Gambacciani M, Ciaponi M, Cappagli B, Genazzani AR. Effects oflow-dose continuous combined conju-gated estrogen and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol 2001;185:1180–5
   PubMed Web of Science ®Google Scholar
• Davies KM, Heaney RP, Recker RR, et al. Hormones, weight change and menopause. Int J Obes Relat Metab Disord 2001;25:874–9
   PubMed Web of Science ®Google Scholar
• Matthews KA, Abrams B, Crawford S, et al. Body mass index in mid-life women: relative influence of menopause, hormone use, and ethnicity. Int J Obes Relat Metab Disord 2001;25:863–73
   PubMed Web of Science ®Google Scholar
• Rolnick SJ, Kopher RA, Compo RB, et al. Provider attitudes and self-reported behaviors related to hormone replacement therapy. Menopause 1999;6: 257–63
   PubMedGoogle Scholar
• Torgerson DJ, Bell-Seyer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285:2891–7
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047–59
   PubMed Web of Science ®Google Scholar
• Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589–93
   PubMed Web of Science ®Google Scholar
• Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk, estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328–32
   PubMed Web of Science ®Google Scholar
• Schairer C, Lubin J, Troisi R, etal. Menopausal estro-gen and estrogen/progestin replacement therapy and breast cancer risk. JAMA 2000;283:485–91
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histo-logy in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370–5
   PubMed Web of Science ®Google Scholar
• Grodstein F, Newcomb PA, Stampfer MJ. Post-menopausal hormone therapy and the risk of colo-rectal cancer: a review and meta-analysis. Am J Med 1999;106:574–82
   Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605–13
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, et al.; for the HERS Research Group. Cardiovascular disease out-comes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 2002;288: 49–57
   Google Scholar
• Hulley S, Furberg C, Barrett-Connor E, et al.; for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years ofhormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 2002;288: 58–66
   Google Scholar
• Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;363:419–27
   Google Scholar